Adefovir dipivoxil

Drug Profile

Adefovir dipivoxil

Alternative Names: Adesera; Bis-POM PMEA; GS 0840; GS 840; Hepsera; Piv2PMEA

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Institute of Organic Chemistry and Biochemistry (Prague); Rega Institute for Medical Research
  • Developer Gilead Sciences; Institute of Organic Chemistry and Biochemistry (Prague)
  • Class Analgesics; Anti-inflammatories; Antiretrovirals; Phosphonic acids; Purine nucleotides; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; Hepatitis B virus replication inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis B
  • Discontinued HIV infections; Rheumatic disorders

Most Recent Events

  • 09 Dec 2005 Launched for Hepatitis B in Spain (PO)
  • 09 Dec 2005 Registered for Hepatitis B in Greece (PO)
  • 09 Dec 2005 Data presented at the 56th Annual Meeting and Postgraduate Course of the American Association for the Study of Liver Diseases (AASLD-2005)have been added to the Viral Infections therapeutic trials section ,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top